Compare ONMD & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONMD | FLNA |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 30.0M |
| IPO Year | 2021 | 2000 |
| Metric | ONMD | FLNA |
|---|---|---|
| Price | $5.36 | $0.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 25.8K | ★ 358.7K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,359,000.00 | ★ $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 111.35 | N/A |
| 52 Week Low | $0.63 | $0.43 |
| 52 Week High | $115.00 | $2.03 |
| Indicator | ONMD | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 29.61 |
| Support Level | $3.86 | N/A |
| Resistance Level | $39.25 | $0.68 |
| Average True Range (ATR) | 0.52 | 0.05 |
| MACD | 0.75 | -0.01 |
| Stochastic Oscillator | 59.81 | 9.70 |
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.